Eli Lilly and Company LLY reported third-quarter 2024 adjusted earnings per share (“EPS”) of $1.18, which missed the Zacks ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...

The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...

Weight loss jabs could soon be given to tens of thousands of people in the UK. It is planned the new scheme would lower rates of obesity and ease the burden on the NHS - but people are being ...

Certain dosages of the GLP-1 receptor agonists dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy), and liraglutide (Victoza, Saxenda) are still in shortage. Bothersome menopause symptoms like ...

GLP-1 agonists help to lower blood sugar and aid in weight loss. Drugs in this class include Byetta (exenatide), Victoza (liraglutide), Trulicity (dulaglutide), and Ozempic (semaglutide) among others.

I insisted on a replacement medicine, and he prescribed Trulicity. The cost was terribly high. The first three months was realistic, then I went into the donut hole. Should people like me just ...

The company is one of the two global leaders in diabetes with blockbuster products in Trulicity and recently launched Mounjaro (tirzepatide) to serve this large underserved market. To date ...

The Trulicity pen -- an injectable drug for patients to manage their type 2 diabetes -- has been around for quite some time. According to Drugs.com, the medication was first approved by the U.S. Food ...